Results There were 148 children who completed 217 Bayley Scales of Infant and Toddler Development, 3rd edition, examinations (group 1, n = 132; group 2, n = 85). Neurodevelopmental score distributions significantly shifted downward compared with test norms at 1 and 2 years of age. Multivariate analysis identified ascites (OR, 3.17; P = .01) and low length z-scores at time of testing (OR, 0.70; P < .04) as risk factors for physical/motor impairment; low weight z-score (OR, 0.57; P = .001) and ascites (OR, 2.89; P = .01) for mental/cognitive/language impairment at 1 year of age. An unsuccessful hepatoportoenterostomy was predictive of both physical/ motor (OR, 4.88; P < .02) and mental/cognitive/language impairment (OR, 4.76; P = .02) at 2 years of age.
Conclusion Participants with biliary atresia surviving with native livers after hepatoportoenterostomy are at increased risk for neurodevelopmental delays at 12 and 24 months of age. Those with unsuccessful hepatoportoenterostomy are >4 times more likely to have neurodevelopmental impairment compared with those with successful hepatoportoenterostomy. Growth delays and/or complications indicating advanced liver disease should alert clinicians to the risk for neurodevelopmental delays, and expedite appropriate interventions. (J Pediatr 2018; 196:139-47 ).
Trial registration Clinicaltrials.gov: NCT00061828 and NCT00294684. B iliary atresia is the most common cause of chronic progressive liver disease in children, manifesting as cholestatic jaundice shortly after birth. It results from an inflammatory and fibrosing obstruction of extrahepatic bile ducts and abnormalities of the intrahepatic bile ducts. 1 The primary treatment is surgical hepatoportoenterostomy (HPE) performed as early as possible in an attempt to reestablish biliary flow. 2 Despite surgical treatment, most patients require liver transplant in childhood, 3 but survival with native liver into school age 4 and adulthood [5] [6] [7] [8] is achievable, and understanding the challenges these patients may encounter at the earliest phase possible is key. A recent prospective study of infants with biliary atresia demonstrated that failure to achieve a serum total bilirubin (TB) level of <2.0 mg/dL in the first 3 months after HPE is associated with increased risk of various medical complications, including ascites, coagulopathy, and failure to thrive. 9 However, neurodevelopmental outcomes were not evaluated. Prior single-center reports describing neurodevelopmental functioning in infants with biliary atresia before liver transplantation [5] [6] [7] [8] were limited by small samples. Neurodevelopmental data from a large, contemporaneous, multicenter cohort of young patients with biliary atresia with native liver followed longitudinally can better inform intervention strategies aimed at improving overall outcomes for this population.
The Biliary Atresia Research Consortium was established in 2002 by the National Institutes of Health to improve understanding of the etiology of biliary atresia, its natural history, and clinical outcomes, and to develop interventional strategies to improve outcomes. The Biliary Atresia Research Consortium was expanded into the Childhood Liver Disease Research Network (ChiLDReN) in 2009. In this prospective, multicenter study, neurodevelopmental outcomes at 1 and 2 years of age were assessed in a cohort of children with biliary atresia who were alive with a native liver and followed longitudinally in ChiLDReN. We hypothesized that patients with biliary atresia with their native livers at 1 and 2 years of age would exhibit significant neurodevelopmental delays and that specific demographic and clinical variables would be predictive of worse neurodevelopmental outcomes.
Methods
Study participants were infants with biliary atresia enrolled in the ChiLDReN's Prospective Study of Infants and Children with Cholestasis (PROBE) Protocol (Clinicaltrials.gov: NCT00061828) between July 1, 2004, and November 1, 2012, who underwent HPE at a ChiLDReN site. Informed consent was obtained from parents or guardians and the protocol was carried out under institutional review board approval. A subset of these infants with biliary atresia with a birth weight of >2 kg was co-enrolled in the Steroids in Biliary Atresia Randomized Trial (START), a prospective, randomized double-blinded, placebo-controlled trial of corticosteroids as adjunctive therapy following HPE for biliary atresia (Clinicaltrials.gov: NCT00294684). 10 Exclusion criteria for this present study included a birth weight of ≤2000 g, acute liver failure, previous hepatobiliary surgery (other than HPE), sepsis, hypoxia, shock, malignancy, primary hemolytic disease, parenteral nutritionassociated cholestasis, extracorporeal membrane oxygenationassociated cholestasis, or liver transplantation.
Data Collection
Data were collected prospectively and entered into a centralized database. Baseline data included patient demographics, medical history (age at HPE, the presence of biliary atresia splenic malformation syndrome [asplenia or polysplenia], family history, and laboratory studies). 9 START randomization group (START steroid or START placebo) or PROBE only assignment were also recorded. Research visits were scheduled 1, 2, 3, and 6 months after HPE, and then at 12, 18, and 24 months of age. Longitudinal data included anthropometry measures, liver biochemical values, and interval history of ascites, cholangitis, spontaneous bacterial peritonitis, gastrointestinal bleeding, and nasogastric feeding within the preceding year. Response to HPE was dichotomized into 2 groups based on serum TB levels in the first 3 months after HPE. 9 "Unsuccessful HPE" was defined for those patients never achieving a TB of <2.0 mg/ dL (34.2 µmol/L) in the first 3 months after HPE. Successful HPE was defined for those patients having any TB of <2.0 mg/ dL (34.2 µmol/L) within the first 3 months after HPE. neurodevelopmental testing was performed at 1 and 2 years of age (±2 months).
Neurodevelopmental Assessment Measures
The Bayley Scales of Infant Development, 2nd edition (BSID-II), was used to assess neurodevelopmental outcomes through January 2010. 11 Starting in February 2010, all participants who were new to the study completed the updated Bayley Scales of Infant and Toddler Development, 3rd edition (Bayley-III). 12 However, participants previously tested with the BSID-II at group 1, were retested with the BSID-II version at 2 years of age to be consistent. Both versions are normed for use between patients at 1 and 42 months of age, and involve a standard series of developmental play tasks that are organized into scales yielding standardized scores (mean = 100 ± 15). The Bayley-III improved on the BSID-II with significant changes in test structure, updated norms, and improved psychometrics. Participants assessed with the BSID-II completed the "mental" and "physical" scales; those assessed with the Bayley-III completed "cognitive," "language," and "motor" scales.
Statistical Analyses
We used descriptive statistics to report continuous and categorical neurodevelopmental outcomes, and all demographic and other clinical characteristics. The 1-sample t test was used to determine whether the mean Bayley scores in our sample were lower than the test norms (100 ± 15). Domain scores for each Bayley version (BSID-II-physical/mental; or Bayley-III-motor/cognitive/language) were categorized as ≥100 (z-score ≥ 0), 85-99 (z-score between 0 and −1), and <85 (z-score < −1). The c 2 test was used to compare the distribution of Bayley scores in the study cohort in these 3 bins to the normal population. P ≤ .05 was considered statistically significant.
Because of the significant changes to the construction and content of the scales, BSID-II and Bayley-III scores are only modestly correlated and are not equivalent. We combined results from the 2 Bayley versions to derive neurodevelopmental out-comes reflecting the entire sample for modeling. The 2 primary neurodevelopmental outcomes were "at risk for physical/ motor delay," defined as either a BSID-II physical score of <85 or a Bayley-III Motor score of <85, and "at risk for mental/ cognitive/language delay," defined as a BSID-II mental score of <85 or a Bayley-III cognitive and/or language score of <85. This approach resulted in the characterization of below average scores on either Bayley version as "at risk" (capturing those performing relatively worse, regardless of measure).
The Bowker test of symmetry was used to assess agreement between the 3 categorical responses for each domain between the participants at 1 and 2 years of age. Associations between patient characteristics and the 2 neurodevelopmental outcomes were determined using logistic regression models. In univariate analyses, risk factors were included one at a time.
In multivariate analysis, we first included all risk factors of interest and a backward stepwise selection procedure was used. P < .10 was used as both inclusion and exclusion criteria in the stepwise selection procedure. Acknowledging the widely reported systematic differences between BSID-II and Bayley-III scores, Bayley version was adjusted in both univariate and multivariate models. 13 Owing to missing data, multiple imputations were used for multivariate analysis using IVEware (Ann Arbor, Michigan).
14 All other analyses were performed using SAS (SAS, Inc, Chicago, Illinois).
Results
A total of 373 PROBE participants with biliary atresia were identified. Participants who underwent liver transplantation (n = 86), died (n = 15), were withdrawn before 1 year of age (n = 12), or weighed <2 kg at birth (n = 8) did not undergo neurodevelopmental assessment (Figure 1 ; available at www.jpeds.com); 132 of the remaining 252 eligible participants (52%) completed neurodevelopmental testing at 1 year of age, and 85 (43%) of 196 eligible had neurodevelopmental testing at 2 years of age. Eligible participants with neurodevelopmental testing at 1 year of age (n = 132) were more likely than those who were eligible but not tested (n = 120) to be white, non-Hispanic, have college-educated parents, and have a successful HPE (P < .04). Similarly, participants tested at 2 years of age (n = 85) were more likely than those who were eligible but not tested (n = 111) to be white and have collegeeducated parents (P < .04; data not shown). Figure 1 provides details of sample ascertainment. A total of 217 completed Bayley assessments from 148 participants were available for the final analysis. Table I provides the demographic, clinical, and medical characteristics for group 1 and group 2 participants. Participants at 1 year of age had more medical events in the preceding year than participants at 2 years of age, including ascites (29% vs 14%) and cholangitis (51% vs 18%). At 1 year of age, among 150 participants with successful HPE who were eligible for neurodevelopmental testing, 91 (61%) completed neurodevelopmental testing, compared with 29 of 78 (37%) with unsuccessful HPE (P = .0006). This was seen again at 2 years of age, with 67 of 133 eligible participants (50%) with successful HPE completing testing, whereas only 10 of 39 eligible participants (26%) with unsuccessful HPE completing testing.
Bayley Scores in Group 1 and Group 2 Participants
Participants completing the 2 Bayley versions did not differ significantly in terms of sex, race, ethnicity, and/or highest household education. Table II (available at www.jpeds.com) provides mean Bayley scores by measure, scale, and age. At group 1 year, the mean participant scores on all BSID-II and all but one Bayley-III scale (cognitive) were significantly lower than test norms with medium to large effect sizes (0.50-1.15). The Bayley-III cognitive scale mean trended toward significance (effect size 0.21). At 2 years of age, the mean scores for those tested with the BSID-II continued to show robust differences from test norms (medium effect sizes, 0.65-0.72). Those tested with Bayley-III showed more modest differences from test norms on cognitive and motor scales (small effect sizes, 0.30-0.43), and no difference on the language scale.
As seen in Figure 2 , the distribution of scores at 1 year of age was shifted downward, with a higher proportion of belowaverage scores than expected compared with the normal population, for all BSID-II and Bayley-III scales except cognitive (P < .05). At 1 year of age, participants' scores were <85 at least twice the expected rate on BSID-II physical and Bayley-III motor scales (59% and 32% vs 16% expected), and the BSID-II mental and Bayley-III language scales (38% and 33% vs 16% expected). At 2 years of age, scores were still shifted downward for those completing the BSID-II, but differences from the expected normal distribution were not significant on Bayley-III. Sixty-nine participants completed neurodevelopmental testing (45 BSID-II and 21 Bayley-III) at both 1 and 2 years of age, and used the same Bayley version each time. The distribution of motor and cognitive subdomain scores did not change significantly over time in these subjects.
Predictors for Being "At Risk for Physical/Motor Delay"
Results of univariate and multivariate analyses identifying at risk for physical/motor delay predictors are reported in Table III . Univariate analysis identified older age at HPE, the presence of ≥1 medical complications (ascites or gastrointestinal bleeding in the prior year or thrombocytopenia at testing), ascites alone in the prior year, and decreased length z-scores at time of testing as risk factors for physical/motor impairment at 1 year of age. Unsuccessful HPE was also identified a risk factor for physical/motor delay at 1 and 2 years of age. In multivariate analysis, only ascites (OR, 3.17) and lower length z-score (OR, 0.70) were associated independently with a higher risk of physical/motor impairment in participants at 1 year of age, and unsuccessful HPE remained the unique predictor of higher risk at 2 years of age (OR, 4.88).
Predictors for Being at Risk for Mental, Cognitive, or Language Delay
Univariate and multivariate analyses of risk factors associated with mental/cognitive/language delay are provided in May 2018 ORIGINAL ARTICLES Table IV . At group 1 year, univariate analysis identified 5 significant predictors of mental/cognitive/language delays: low weight and length z-scores, higher recent serum TB level, ascites, and older age at HPE. Only race, low weight at the time of neurodevelopmental testing (OR, 0.57), and ascites within the prior year (OR, 2.89) retained significance on the multivariate analysis. Univariate analysis of participants at 2 years of age revealed higher level of serum TB at testing, older age at HPE, unsuccessful HPE, and presence of medical complications as risk factors for impairments in mental/cognitive/language development, whereas household education of college or greater was protective. On multivariate analysis, only 2 variables retained significance: unsuccessful HPE (OR, 4.76) and household educational level (OR, 0.26).
Successful vs Unsuccessful HPE and Being At Risk for Neurodevelopmental Delay Outcomes
At 1 year of age, 53% of participants (46/87) with successful HPE were identified as being at risk for physical/motor delay compared with 77% of participants (20/26) with unsuccessful HPE. At 2 years of age, 25% of participants (16/64) with successful HPE were identified as at risk in this domain, compared with 66% of patients (6/9) with unsuccessful HPE; 38% of group 1 participants (33/88) and 33% group 2 participants (22/66) of with successful HPE were at risk for mental/ cognitive/language delay, compared with 55% of group 1 participants (16/29) and 67% of group 2 participants (6/9) with unsuccessful HPE.
Discussion
In this multicenter study, we demonstrate that young children with biliary atresia surviving with native livers after HPE are at increased risk for neurodevelopmental delays at 1 and 2 years of age compared with test norms. Markers of advanced liver disease such as ascites and growth deficits were associated with worse neurodevelopmental outcomes. Neurodevelopmental scores remained stable across categories (≥100, 85-99, <85) from group 1 to group 2 in those tested at both times. Children with biliary atresia living with an unsuccessful HPE have a 2-5 times higher incidence of delays in both physical/motor skills as well as mental/cognitive/language development during the first 2 years of life. Recent research initiatives have focused largely on neurocognitive outcomes in cohorts of pediatric liver transplantation recipients, comprised largely of participants with biliary atresia and show that developmental delays are prominent at the time of listing and after transplantation. 15, 16 Only a handful of small, single-center studies have examined neurodevelopmental outcomes specifically in infants with biliary atresia and their native livers, with cognitive and motor delays most consistently reported in both before transplantation 5, 6, 8, 17 as well as at 1 year after liver transplantation. 17 In our study, unsuccessful HPE was associated with a greatly increased risk of neurodevelopmental delays, with 75% at risk in the physical/motor domain and 50% at risk for mental/ cognitive/language delays at 1 year of age. Nevertheless, even patients with biliary atresia with evidence of a successful HPE remain vulnerable, with 1 in 4 at risk for physical/motor delays, and 1 in 3 at risk for mental/cognitive/language delays at 2 years of age. Given that the median age at liver transplantation is <2 years, our results underscore the importance of identifying and addressing those at risk for neurodevelopmental delays swiftly, even when they do not meet indications for liver transplantation. Previous detailed characterization of children with biliary atresia with their native liver ≥5 years after HPE (ie, who are not listed for liver transplantation) revealed progressive clinical or biochemical evidence of chronic liver disease and its consequences. 18 Strategies are needed to identify those most at risk for neurodevelopmental delays and enable interventions at the earliest age possible to ensure optimal outcomes for patients with this chronic childhood liver condition.
Infancy and early childhood is a time of critical brain development, and an important period for neurodevelopmental surveillance, especially in children with chronic illnesses. Infants diagnosed with biliary atresia are potentially more vulnerable given the absence of alternate treatments and the need for timely surgical intervention (HPE) requiring prolonged general anesthesia within the first months of life. However, a recent study examining 336 infants found few significant effects of general anesthesia in the first year of life on neurodevelopmental outcomes compared with controls. 19 Additionally, interim results from 2 long-term studies-one a randomized trial comparing general anesthesia with regional anesthesia, 20 and another looking at sibling pairs 21 -noted no effect of general anesthesia on neurodevelopmental outcomes using standardized testing after a single exposure to general anesthesia. Given the essential role of general anesthesia for surgical procedures (like the HPE) to be performed safely in infants, concern for general anesthesia on the developing brain should not result in a delay in the timely completion of the HPE procedure, because it is likely that the neurodevelopmental issues are related to the primary conditions and comorbidities, and not to the use of general anesthesia. 20, 21 Our study found that children with biliary atresia with ascites at 1 year of age were 3 times more likely to have physical/ motor delays. The presence of ascites, a known marker of advanced liver disease, may impair motor development owing to abdominal distension that could potentially inhibit normal infant movement and exploration. 6, 7, 17, 22 Advanced liver disease may also affect motor development through its effect on the brain and its association with poor nutritional status and loss of muscle mass. Other markers of advanced liver disease, such as international normalized ratio, have also been reported to correlate negatively with both gross and fine motor performance, 6 although this outcome was not found in our cohort. Motor deficits have been found to persist through school age in patients with chronic liver disease. 23 An association has been found between motor deficits and long-term outcomes in pediatric acute liver failure, 24 and in children with extrahepatic portal vein obstruction with signs of hyperammonemia and cerebral edema on imaging. 25, 26 Ascites was also a significant predictor of mental/cognitive/language attainment at 1 and 2 years of age. A diseased liver with a reduced capacity to metabolize a variety of potentially cerebrotoxic substances in the blood may also contribute to cognitive deficits in infants with advanced liver disease and portal hypertension. 7 Failure to thrive is a serious consequence of chronic liver disease and is associated with increased morbidity and mortality. 27 Our study found that lower weight and length z-scores at testing were significant predictors of mental/ cognitive/language delay at 1 year of age and lower length z-scores predicted risk for physical/motor delay at 1 year, but neither length nor weight predicted outcome at 2 years of age. In our cohort, participants surviving to group 2 with their native livers had mean length and weight z-scores much closer to the average than participants tested at 1 year of age, who underwent liver transplantation or died before group 2 testing. Unfortunately, growth delays related to early malnutrition have consistently predicted long-term neurocognitive outcomes in Bold values refer to a significance level of P < 0.05. n/a, not applicable; NE, not estimable. *One or more of the following: history of ascites, or gastrointestinal bleed in preceding year; platelets <150 at time of testing. †Stepwise selection process was used to arrive at final models. Only variables with P ≤ .05 remain in the final models. ‡OR > 1.0 indicates increased risk for neurodevelopmental delay.
THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 196 patients with chronic liver well after liver transplantation, 27 suggesting an early and possibly irreversible impact on brain development. These findings suggest that optimizing early nutrition and growth in infants with biliary atresia could potentially have important ramifications for neurodevelopmental outcomes.
In our study, a small subsample was simultaneously enrolled in a blinded, randomized, placebo-controlled study of corticosteroids as adjunctive therapy after HPE. 28 Steroid use was not associated with neurodevelopmental outcomes in these patients. The limited research available on the cognitive effects of corticosteroids in children suggests potential acute worsening in areas such as attention, memory, and executive functioning 29, 30 that are not measurable in infants. Thus, prospective assessment of relevant functional domains later in development is needed before concluding that corticosteroids have no impact on neurodevelopmental outcomes in pediatric patients with biliary atresia.
Despite examining the neurodevelopmental outcomes in the largest prospective cohort of infants with biliary atresia to date, we acknowledge potential limitations and biases of this study. First, our sample reflects at best 50% attainment of eligible participants. Although specific reasons for nonparticipation were not available, neurodevelopmental data collection in infants (particularly those with a serious chronic disease or those who are extremely ill) is challenging. Second, a much greater proportion of participants with successful HPE underwent neurodevelopmental testing at both time points compared with eligible participants with unsuccessful HPE, indicating that our sample was likely healthier than the general population with biliary atresia. Indeed, our study did not capture children with unsuccessful HPE who were transplanted (or died) before 1 year of age, and participants with neurodevelopmental testing at 2 years of age were healthier than those with testing at 1 year of age for the same reason (dropout owing to death or liver transplantation after group 1). This bias toward recruitment Bold values refer to a significance level of P < 0.05. *One or more of the following: history of ascites, or gastrointestinal bleed in preceding year; platelets <150 at time of testing. †Stepwise selection process was used to arrive at final models. Only variables with P ≤ .05 remain in the final models. ‡OR > 1.0 indicates increased risk for neurodevelopmental delay.
of healthier participants is common in research studies, and actually underscores the significance of these findings. Finally, a particular challenge to the interpretation of this database was the midstudy shift in Bayley version. The test structure changed significantly, with a major revision and redistribution of items from 2 core scales on the BSID-II to 3 on the Bayley-III, thereby eliminating the possibility of simply combining scores across versions for analysis. Validity studies show only modest correlations between the 2 versions, with significantly lower scores on BSID-II compared with Bayley-III editions. 12, 13 Indeed, this pattern held in our own sample. Other studies have also faced this challenge, and used various strategies to attempt to equate the 2 versions by conversion algorithm, regression analysis, or setting a higher cutpoint on the Bayley-III cognitive (and language) scales compared with BSID-II mental scale. [31] [32] [33] [34] Although these strategies have all assumed that the Bayley-III underestimates neurodevelopmental delay, there is now accumulating evidence that the BSID-II overestimates neurodevelopmental delay, and that the Bayley-III scores are actually more valid.
11 Some studies are reporting high correlations of 0.81 and 0.78 between Bayley-III cognitive and language scores at 2 years of age with the Wechsler Preschool and Primary Scale of Intelligence-III, and the full-scale IQ at 4 years of age in preterm children, with 81% of studied participants maintaining the same developmental classification from the Bayley-III to the Wechsler Preschool and Primary Scale of Intelligence-III. 35, 36 In our study, we addressed this dilemma with the definition of at-risk groups for modeling, which allowed the capture of all patients with scores at the lower end of the distribution, regardless of version or scale. We also ensured that our univariate and multivariate analyses adjusted for Bayley version. Only longitudinal assessment of this population with biliary atresia will determine if the risk for neurodevelopmental delays found within the first 2 years will persist at older ages; these studies are in progress to document development and evaluate the impact of interventions.
In conclusion, this study provides benchmarks for neurodevelopmental outcomes expected in 1-and 2-yearold children with biliary atresia with their native livers. These young children remain at significant risk for neurodevelopmental impairments, including both physical/ motor and mental/cognitive/language domains, even in those patients with a successful HPE and who are not listed for pediatric liver transplantation. Stunted growth and complications indicative of advanced liver disease are associated with worse neurodevelopmental outcomes. These findings suggest that strategies to promote successful HPE surgery (such as earlier diagnosis and intervention) and to optimize growth and nutrition may improve neurodevelopmental outcomes in this vulnerable population. THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 196 147.e3
